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Adult mesenchymal stromal/stem cells (MSCs) are a valuable source of multipotent progenitors for tissue
engineering and regenerative medicine, but may require to be genetically modified to widen their efficacy in
therapeutic applications. For example, overexpression of the angiogenic factor vascular endothelial growth
factor (VEGF) at controlled levels is an attractive strategy to overcome the crucial bottleneck of graft vascu-
larization and to avoid aberrant vascular growth. Since the regenerative potential of MSCs is rapidly lost during
in vitro expansion, we sought to develop an optimized technique to achieve high-efficiency retroviral vector
transduction of MSCs derived from both adipose tissue (adipose stromal cells, ASCs) or bone marrow (BMSCs)
and rapidly select cells expressing desired levels of VEGF with minimal in vitro expansion. The proliferative peak
of freshly isolated human ASCs and BMSCs was reached 4 and 6 days after plating, respectively. By performing
retroviral vector transduction at this time point, > 90% efficiency was routinely achieved before the first passage.
MSCs were transduced with vectors expressing rat VEGF164 quantitatively linked to a syngenic cell surface
marker (truncated rat CD8). Retroviral transduction and VEGF expression did not affect MSC phenotype nor
impair their in vitro proliferation and differentiation potential. Transgene expression was also maintained during
in vitro differentiation. Furthermore, three subpopulations of transduced BMSCs homogeneously producing
specific low, medium, and high VEGF doses could be prospectively isolated by flow cytometry based on the
intensity of their CD8 expression already at the first passage. In conclusion, this optimized platform allowed the
generation of populations of genetically modified MSCs, expressing specific levels of a therapeutic transgene,
already at the first passage, thereby minimizing in vitro expansion and loss of regenerative potential.
Introduction
Adult mesenchymal stem/stromal cells (MSCs) are apopulation of multipotent progenitors, capable of gen-
erating bone, cartilage, fat, and possibly other mesodermal
tissues and represent a fundamental tool in regenerative
medicine.1,2 MSCs have been described in many tissues as a
pericyte-like population in close association with blood ves-
sels,3 raising the intriguing possibility that they may reside in
the vascularized stroma of every tissue. However, the most
commonly used and characterized MSCs are derived from
bone marrow (BMSCs) and adipose tissue (adipose stromal
cells, ASCs), due to their abundance and ease of harvesting.4,5
Despite their potential, it may be desirable to genetically
modify MSCs in order to increase their survival and/or dif-
ferentiation in therapeutic applications. For example, sponta-
neous vascularization of tissue-engineered grafts in vivo is too
slow to allow survival of progenitors in constructs larger than
a few millimeters. To overcome this bottleneck in the gener-
ation of clinical-size grafts, it is necessary to increase their
ability to rapidly attract a vascular supply from the host, for
example, by overexpressing an angiogenic factor from the
implanted progenitors.6–8
Vascular endothelial growth factor (VEGF) is the master
regulator of vascular growth both in embryonic development
and adult tissues.9 When expressed at the appropriate dose,
VEGF can start the complex cascade of events leading to the
formation of stable and functional new blood vessels.10 How-
ever, sustained expression is required for about 4 weeks in or-
der to avoid regression of newly induced unstable vessels.11,12
Nonintegrating gene therapy vectors are progressively
lost during cell expansion and lead to short-term and
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variable expression. Gene expression is thus less controllable,
making it challenging to achieve a desired therapeutic effect.
Integrating vectors, such as retroviral vectors on the other
hand, replicate with the host genome and ensure constant
expression throughout cell expansion.13,14
MSCs have been shown to rapidly lose their differentia-
tion potential during in vitro expansion.15,16 Therefore it is
crucial that genetic modification takes place both with high
efficiency, in order to minimize the need for cell selection,
and with minimal in vitro manipulation of progenitors.
Therefore, here we sought to develop an optimized tech-
nique to achieve rapid and high-efficiency transduction of
primary MSCs from both bone marrow and adipose tissue
with minimal in vitro expansion, together with high-
throughput purification of the progenitor populations
expressing specific transgene levels based on fluorescence-
activated cell sorting (FACS). The study of in vivo vascular-
ization of critical-size osteogenic grafts seeded with human
MSCs requires a nude rat model, due both to the dimensions
of the constructs and the need to avoid rejection of human
cells. However, nude rats are tolerant to xenogenic cells, but
not secreted molecules, and can develop antibodies against
them. Therefore, we generated genetically modified human
MSCs overexpressing rat VEGF in view of subsequent in vivo
experiments in rats with this tool. Greater than 90% trans-
duction efficiency of freshly isolated BMSCs and ASCs could
be routinely achieved and FACS purification was possible
already at the time of the first passage, while no loss of
in vitro proliferation and differentiation potential was caused
by either the genetic modification or the FACS sorting.
Materials and Methods
MSC isolation and culture
Human primary ASCs and BMSCs were isolated from
liposuction and bone marrow aspirates, respectively. The
aspirates were obtained from healthy donors as previously
described after informed consent by the patients and ap-
proval by the local ethical committee. Briefly, subcutaneous
adipose tissue was digested in 0.075% type-II collagenase
(Worthington) in phosphate-buffered saline (PBS) and
plated at a density of 5.5 · 103 nucleated cells/cm2.17 Bone
marrow was subjected to red blood cell lysis18 and plated
at a density of 105 nucleated cells/cm2. Both ASCs and
BMSCs were cultured in a-MEM supplemented with 10%
fetal bovine serum (FBS) (Gibco) and 5 ng/mL fibroblast
growth factor (FGF)-2 (BD Biosciences). Cells were pas-
saged when 80% confluent and replated at a density of
3 · 103 cells/cm2.
Colony forming efficiency assays were performed on
freshly isolated cells as described.19 The proliferation rate
was determined by counting the number of cells at every
passage with a Neubauer chamber (Roth), determining the
number of population doublings from the previous pas-
sage19 and plotting the cumulative doublings against the
time in culture.
Myoblast culture
Primary C57Bl/6 mouse myoblasts were cultured on
collagen-coated dishes in medium consisting of 40% F10,
40% low-glucose Dulbecco’s modified Eagle’s medium (both
Sigma), supplemented with 20% FBS and 2.5 ng/mL FGF-2,
as previously described.20
Cell cycle analysis
The proportion of actively cycling cells was determined by
measuring their nuclear DNA content by flow cytometry
after staining with propidium iodide as described.21 The data
were analyzed using the cell cycle analysis tool from FlowJo
Software (Tree Star) using the Watson model.22 ASCs (n= 4
donors) and BMSCs (n = 3 donors) from duplicate dishes
were analyzed at each time point.
Retroviral transduction
The optimization experiments were performed with fro-
zen aliquots of a pooled stock of retroviral vector superna-
tant, to ensure the same titer in all conditions. Subsequent
experiments were performed with fresh viral vector super-
natants. Primary MSCs were transduced with previously
described retroviral vectors, carrying the gene for rat
VEGF164 linked through an internal ribosomal entry site
(IRES) to a truncated version of the FACS-quantifiable cell
surface marker truncated rat CD8a,23 according to a high-
efficiency protocol.24 Briefly, MSCs were cultured in 60-mm
dishes and were incubated with retroviral vector superna-
tants supplemented with 8 mg/mL polybrene (Sigma-
Aldrich) for 5min at 37C and centrifuged at 1100g for
30min at room temperature in the dishes, followed by fresh
medium replacement. After initial optimization, all subse-
quent experiments were carried out with cells transduced
twice per day for a total of 4 infection rounds.
Flow cytometry
CD8a expression was assessed by staining with a fluo-
rescein isothiocyanate-conjugated anti-rat CD8a antibody
(clone OX-8; BD Pharmingen), using previously optimized
staining conditions to ensure complete saturation of the
CD8a molecules expressed on all cells in the heterogeneous
transduced population,23 that is, 2 mg of antibody/106 cells in
200 mL of PBS with 5% bovine serum albumin.
Expression of MSC surface markers was assessed by
staining with specific antibodies against CD31 (clone WM59;
BD Pharmingen), CD34 (clone 581; BD Pharmingen), KDR/
VEGFR2 (clone 89106; R&D Systems), CD73 (clone AD2; BD
Pharmingen), CD90 (clone 5E10; BD Pharmingen), and
CD105 (clone SN6; AbD Serotec). All antibodies were used at
a 1:20 dilution except for CD90 (1:100). Aspecific binding
was measured by staining with appropriate isotype control
antibodies. Data were acquired with a FACSCalibur flow
cytometer (Becton Dickinson) and analyzed using FlowJo
software (Tree Star). Cell sorting was performed with the
Influx cell sorter (Becton Dickinson).
MSC immunostaining
Fifty percent confluent MSC cultures were fixed with 4%
formalin, blocked for 1 h with 10% calf serum in PBS,
and incubated with an antibody against rat CD8a (clone
OX-8, BD Pharmingen; 1:200), followed by an Alexa 488–
conjugated chicken anti-mouse IgG (Invitrogen; 1:500).
Nuclei were stained with 4¢,6-diamidino-2-phenylindole
(DAPI) (Invitrogen).
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In vitro differentiation
Adipogenic differentiation was induced as previously
described.17 Briefly, subconfluent cell layers were treated
with 10mg/mL insulin, 10 - 5 M dexamethasone, 100 mM in-
domethacin, and 500 mM 3-isobutyl-1-methyl xanthine for
72 h and subsequently with 10 mg/mL insulin for 24 h, re-
peating this 96-h treatment cycle four times. Lipid droplets
were detected with Oil Red-O staining.
Osteogenic differentiation was induced by culturing MSCs
with a-MEM supplemented with 10% FBS, 100 nM dexa-
methasone, 10mM b-glycerophosphate, and 0.05mM ascor-
bic acid-2-phosphate for 3 weeks, as previously described.17
Calcium deposits were detected with Alizarin Red staining.
Quantitative real-time reverse transcriptase
polymerase chain reaction
Total mRNA was isolated using the RNeasy Mini Kit
(Qiagen) and cDNA was synthesized with the Superscript III
Reverse Transcriptase (Invitrogen).
Quantitative real-time reverse transcriptase polymerase
chain reaction (qRT-PCR) was performed on a 7300 AB
thermocycler (Applied Biosystem) to quantify the expression
of the following genes: human cbfa-1/Runx2 (Forward:
CGTTACCCGCCATGACAGTA; Reverse: GCCTTCAA
GGTGGTAGCCC; Probe: CCACAGTCCCATCTGGTACC
TCTCCG; primers = 300 nM and probe = 100 nM)25; PPAR-g
(Applied Biosystems assay Hs00234592_mL; primers =
900 nM and probe = 250 nM). To quantify expression of the
retroviral cassette, a specific primers-and-probe set was de-
signed with the Primer Express 3 software (Applied Bio-
systems) to recognize the IRES sequence (Forward:
GCTCTCCTCAAGCGTATTCAACA; Reverse: CCCCAGAT
CAGATCCCATACA; Probe: CTGAAGGATGCCCAGAAG
GTACCCCA; primers = 400 nM and probe = 400 nM). Gly-
ceraldehyde 3-phosphate dehydrogenase was used as a
housekeeping gene (Forward: TAAAAGCAGCCCTGGTG
ACC; Reverse: ATGGGGAAGGTGAAGGTCG; Probe:
CGCCCAATACGACCAAATCCGTTGAC; primers = 300 nM
and probe = 150 nM).26 Two independent cDNA samples/
condition/donor were analyzed in triplicate with the fol-
lowing cycling parameters: 50C for 2min, followed by 95C
for 10min and 45 cycles of denaturation at 95C for 15 s and
annealing/extension at 60C for 1min.
Enzyme-linked immunosorbent assay
VEGF production was quantified in cell culture superna-
tants using a Quantikine rat VEGF immunoassay enzyme-
linked immunosorbent assay (ELISA) kit (R&D Systems).
One milliliter of fresh medium was incubated on MSCs
cultured in 60-mm dishes (for expansion cultures) or in six-
wells (at the end of differentiation experiments) in duplicate
for 4 h, filtered, and frozen. Results were normalized by the
number of cells in each dish and the time of incubation.
Statistics
Data are presented as means – standard error. The sig-
nificance of differences in multiple comparisons was eval-
uated using one-way analysis of variance followed by the
Bonferroni test. p < 0.05 was considered statistically sig-
nificant.
Results
Optimization of MSC transduction
Since retroviral vectors efficiently transduce only dividing
cells, we first sought to determine the earliest time after
isolation and plating when ASCs and BMSCs enter the cell
cycle and proliferation is at its peak. Cell cycle analysis was
performed on samples from 3 independent donors every day
from the initial plating to the time of first confluence, which
was reached consistently by day 12 and 14 for ASCs and
BMSCs, respectively. ASCs reproducibly reached a prolifer-
ation peak 4 days after isolation (52.2% – 5.0% of cycling
cells) that was maintained until day 7, after which replication
declined with increasing confluence (Fig. 1A). BMSCs dis-
played a higher variability in the first days, but their growth
trend was similar, proliferation reached its maximum on day
6 (54.7%– 5.5%) and declined after day 10 (Fig. 1B).
Based on these results, we determined the optimal time to
start transduction to be on day 4 after isolation for ASCs and
day 6 for BMSCs. Cells were transduced twice per day up to
six times with a retroviral vector expressing the cell surface
marker CD8 and the transduction efficiency was evaluated
after each round by FACS quantification of the CD8-positive
cells. The majority of the increase in the number of trans-
duced cells took place during the first four rounds for both
ASCs and BMSCs (Fig. 1C, D), while the last two rounds
only contributed marginal improvement. Therefore, it was
determined that four rounds of transduction would provide
a suitable balance between efficacy and cell manipulation
and this protocol was used to generate all cell populations
for further analysis described below.
Generation of FACS-sortable MSCs
Freshly isolated ASCs and BMSCs were transduced ac-
cording to the optimized protocol with a bicistronic retro-
viral vector coexpressing rat VEGF164 (VEGF) and a
truncated version of rat CD8a (CD8) as a FACS-quantifiable
cell surface marker, joined through an internal ribosomal
entry site (IRES) that allows the translation of two proteins
from the same mRNA at a fixed ratio27 (Fig. 2). A retroviral
vector expressing only CD8 was used to generate control
cells. These genetically modified populations were used for
further analysis (Fig. 2).
Using freshly produced viral vector supernatants with the
optimized protocol described previously, a transduction ef-
ficiency > 90% was routinely achieved (Fig. 3A, B). Upon
reaching the first confluence, MSCs were FACS purified in
order to remove nontransduced cells and to yield pure CD8-
positive populations (Fig. 3A, B), which were replated for all
subsequent experiments. Neither sorting nor transduction
affected the morphology of ASCs and BMSCs, which ex-
hibited a spindle-shaped phenotype similar to that of the
corresponding naive cells (Fig. 3C, D, bright field). Detection
of membrane CD8 by immunofluorescent staining confirmed
the high efficiency of transduction (Fig. 3C, D, unsorted) and
the lack of nontransduced cells after sorting (Fig. 3C, D,
sorted).
We further investigated whether transduction or VEGF
expression could change the phenotype of MSC populations
or cause the expansion of endothelial subpopulations. For
this purpose the expression of surface markers specific for
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mesenchymal (CD105, CD90, and CD73) and endothelial
(CD31, CD34, and VEGFR2) cells was analyzed by flow cy-
tometry. Naive ASCs and BMSCs were compared with
mock-transduced cells (centrifuged only) and with CD8- or
VEGF-expressing transduced and sorted cells. As shown in
Table 1, first-passage naive ASCs and BMSCs were almost
uniformly positive for all the analyzed mesenchymal mark-
ers and contained less than 0.5% of endothelial cells. No
significant changes in the mesenchymal phenotype of ma-
nipulated MSCs were caused by transduction and sorting or
by VEGF expression, nor was the ratio of endothelial cells
increased in any condition.
In vitro proliferation and differentiation
of genetically modified MSCs
The effects of transduction and FACS purification on MSC
proliferative potential were assessed by measuring the cumu-
lative population doublings of CD8- and VEGF-expressing
ASCs and BMSCs for eight and nine passages after sorting,
respectively. These were compared with naive cells and
mock-transduced cells that were subjected to the physical
manipulation involved in the transduction protocol, that is,
centrifugation for 30’ in the dish, but in the absence of viral
vector particles. Both transduced ASC and BMSC popula-
tions proliferated more slowly than the naive and centri-
fuged MSCs during the first two passages after sorting
(Fig. 4). However, this effect was temporary and growth of
transduced MSCs resumed at the same rate as control cells
approximately 10 days after the sorting (Fig. 4). Therefore,
transduction and sorting did not affect the intrinsic prolif-
erative potential of MSCs.
The differentiation potential of the same ASC and BMSC
populations toward the adipogenic and osteogenic lineages
was determined in vitro after the first passage and FACS
purification. Mock-transduced, CD8- and VEGF-expressing
ASCs (Fig. 5A) and BMSCs (Fig. 5C) were able to differen-
tiate into both lineages similarly to the naive MSCs.
FIG. 2. Study design. ASCs
and BMSCs were isolated
and transduced with a
bicistronic retroviral vector
coexpressing rat VEGF164
(rVEGF164) and a truncated
version of rat CD8a
(tr. rCD8a). LTR = retroviral
long terminal repeats;
C =packaging signal;
IRES = internal ribosomal
entry site. CD8-positive
MSCs were FACS sorted to
generate pure populations of transduced cells and were analyzed to determine the effects of retroviral transduction and
transgene expression on their phenotype, as well as their in vitro proliferation and differentiation potential. VEGF, vascular
endothelial growth factor.
FIG. 1. Optimization of
MSC retroviral vector trans-
duction. The proportion of
ASCs (A) and BMSCs (B) in
active proliferation (S/G2/M
phases) was assessed by flow
cytometry analysis of nuclear
DNA content after staining
with propidium iodide
during the first 12 to 14 days
after initial plating (n = 3
each). The transduction
efficiency of ASCs (C) and
BMSCs (D) was assessed as a
function of infection rounds
(n = 3 each). The amount of
CD8-positive cells was
determined by FACS after up
to six rounds of transduction
with a CD8-expressing
retroviral vector. Naive MSCs
were used as negative control
(0 rounds). MSCs, mesen-
chymal stromal/stem cells;
ASCs, adipose stromal cells;
FACS, fluorescence-activated
cell sorting; BMSCs, bone
marrow–derived MSCs.
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Interestingly, in ASCs from one donor with poor intrinsic
osteogenic differentiation potential (Fig. 5B), VEGF expres-
sion actually increased osteogenic differentiation compared
with naive, mock-transduced and CD8-expressing cells (Fig.
5B). Differentiation was confirmed by quantifying the ex-
pression of transcription factors that are responsible for ini-
tiating adipogenesis (PPAR-g, Fig. 5D, E) and osteogenesis
(Runx2, Fig. 5F, G) by qRT-PCR. The results confirmed that
ASC and BMSC differentiation along both lineages was not
impaired by retroviral transduction, FACS purification, or
VEGF expression.
Transgene expression is maintained
after cell differentiation
Retroviral vectors integrate in the host genome and their
level of expression can be affected by remodeling of the
surrounding chromatin that accompanies gene activation
FIG. 3. FACS purification
of transduced MSCs.
Representative FACS plots
show that both ASCs (A) and
BMSCs (B) were transduced
with > 90% efficiency (black
plots) and that pure CD8-
positive populations were ob-
tained after sorting (tinted blue
plots). Control naive cells = red
plots. Microscopic images of
naive or VEGF-expressing ASCs
(C) and BMSCs (D), either
before (unsorted) or after
(sorted) FACS purification.
BF= bright field images; CD8=
cells immunostained with an
antirat CD8 antibody (green)
and DAPI (nuclei, in blue).
White arrows indicate the
nuclei of CD8-negative cells in
the unsorted populations (n = 3
each). Size bar = 100 mm. DAPI,
4¢,6-diamidino-2-phenylindole.
Color images available online at
www.liebertonline.com/tec
Table 1. Expression of Endothelial and Mesenchymal Markers by Naive and Transduced
Adult Mesenchymal Stromal/Stem Cells
% of positive cells in ASC populations
Naive Mock CD8 VEGF
Endothelial markers CD31 +/CD34 + 0.2 – 0.1 0.2 – 0.1 0.3 – 0.2 0.1 – 0.1
VEGFR2 + 0.0 – 0.0 0.1 – 0.1 0.5 – 0.2 0.0 – 0.0
Mesenchymal markers CD73 + 94.4 – 5.0 95.7 – 3.5 91.2 – 8.4 91.6 – 8.1
CD90 + 94.4 – 5.2 94.9 – 4.7 90.6 – 8.9 89.3 – 10.1
CD105 + 93.6 – 4.7 91.9 – 3.9 87.7 – 6.5 86.2 – 6.9
% of positive cells in BMSC populations
Naive Mock CD8 VEGF
Endothelial Markers CD31+/CD34+ 0.0 – 0.0 0.0 – 0.0 0.0 – 0.0 0.0 – 0.0
VEGFR2+ 0.0 – 0.0 0.5 – 0.4 0.0 – 0.0 0.1 – 0.1
Mesenchymal markers CD73+ 99.6 – 0.1 99.8 – 0.1 99.7 – 0.1 99.7 – 0.1
CD90+ 89.2 – 3.5 89.0 – 3.2 91.8 – 3.1 93.1 – 1.5
CD105+ 98.9 – 0.4 98.3 – 1.4 99.2 – 0.3 99.0 – 0.5
BMSCs, bone marrow–derived mesenchymal stromal/stem cells; ASCs, adipose stromal cells.
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and repression during differentiation.28 Therefore, we as-
sessed the stability of transgene expression by transduced
and FACS-purified MSCs during differentiation.
Transgene mRNA levels were quantified by qRT-PCR of
the IRES sequence, which is common to the expression cas-
settes in both retroviral vectors used (CD8 and VEGF), so
that the use of a single pair of primers allowed comparisons
between all cell populations (Fig. 6A, B). VEGF protein was
measured by ELISA (Fig. 6C, D). Both assays indicated that
transgene expression did not decline during in vitro adipo-
genic or osteogenic differentiation compared with cells in
expansion medium, and that in some instances it actually
increased.
FACS purification of MSCs expressing
specific VEGF levels
To rapidly purify homogeneous populations expressing
desired levels of VEGF, we employed a technology that we
recently developed with transduced skeletal myoblasts.23,29
FIG. 4. In vitro proliferation
of transduced MSCs. The
in vitro proliferative potential
of CD8- and VEGF-expressing
ASCs (A) and BMSCs (B) was
not impaired compared with
that of naive and mock-
transduced cells over nine
passages after FACS sorting
(n = 3 each).
FIG. 5. In vitro differentia-
tion of transduced MSCs.
Naive, mock-transduced,
CD8- and VEGF-expressing
MSCs were differentiated
in vitro toward the adipogenic
and osteogenic lineages.
(A–C) Oil Red-O staining
(adipogenic) and Alizarin
Red staining (osteogenic) of
control (C-) or differentiated
(Diff.) ASCs (A, B, from two
different donors) and BMSCs
(C) (n= 4 each). Differentia-
tion was confirmed by
quantifying the expression of
PPAR-g (adipogenesis, D, E)
and Runx2 (osteogenesis, F,
G) in expansion and
differentiation conditions by
quantitative real-time PCR
(n = 3 each). The graphs show
relative expression compared
with that of the housekeeping
gene GAPDH. PCR,
polymerase chain reaction;
GAPDH, glyceraldehyde
3-phosphate dehydrogenase.
Color images available online
at www.liebertonline.com/
tec
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Previously established clonal populations of skeletal myo-
blasts transduced with the same ratVEGF-IRES-ratCD8 ret-
rovirus and homogeneously expressing specific VEGF
levels23 were used as reference populations to FACS-sort
transduced MSCs expressing similar CD8 levels on the cell
surface (Fig. 7A). The unsorted transduced BMSC population
expressed on average 142– 14 ng/106 cells/day of rat VEGF
and, after FACS purification, low-, medium-, and high-level
sorted populations produced about 12, 79, and 154 ng/106
cells/day, respectively. As shown in Fig. 7B, these VEGF
amounts were remarkably similar to those produced by the
corresponding reference clonal populations (13, 53, and
155 ng/106 cells/day, respectively). VEGF secretion by the
FACS-purified populations was stable also 5 and 18 days
after sorting (data not shown).
Discussion
In this study we developed a tool to genetically modify
primary human MSCs derived from bone marrow and adi-
pose tissue with high efficiency and rapidly select cells ex-
pressing desired levels of VEGF with minimal in vitro
manipulation, so as to preserve their progenitor properties.
This was achieved by combining an optimized transduction
protocol with a high-throughput FACS-based purification
technology we recently developed.29 Neither retroviral vec-
tor transduction, nor FACS purification, nor expression of
VEGF and the CD8 marker impaired MSC proliferation and
in vitro differentiation potential toward the adipogenic and
osteogenic lineages. Transgene expression was sustained
during in vitro differentiation. Interestingly, we recently
found that similarly transduced and FACS-purified BMSCs,
expressing only the truncated CD8 marker, also displayed no
impairment of their chondrogenic potential both in vitro and
in vivo (Marsano, A., Martin, I., and Banfi, A., unpublished
observations).
The lack of detrimental effects on BMSC properties by
VEGF overexpression was not due to a lack of activity of rat
VEGF on human VEGF receptors. In fact, rat VEGF164 shares
90% amino acid sequence identity with human VEGF165
(http://blast.ncbi.nlm.nih.gov/) and is effective in stimulat-
ing the proliferation of human endothelial cells,30 with a
similar potency as the corresponding human recombinant
factor (ED50 rVEGF164= 0.75–3.75 ng/mL and ED50
hVEGF165 = 1–6 ng/mL), according to manufacturer data
(R&D Systems).
Genetic modification with integrating vectors, such as
retroviruses, ensures consistent long-term expression of
FIG. 6. Transgene expression after in vitro
differentiation. Transgene expression was
quantified in expansion culture (E) or after
adipogenic (A) and osteogenic (O) in vitro
differentiation of CD8- and VEGF-expres-
sing ASCs (A, C) and BMSCs (B, D). Ex-
pression of the transgene mRNA levels was
quantified by qRT-PCR (A, B). VEGF pro-
tein in the supernatants (1mL) was mea-
sured by ELISA and normalized for the
number of cells and time of incubation (C,
D). **p£ 0.01 and ***p £ 0.001 versus cells
cultured in expansion medium (n = 3 each).
qRT-PCR, quantitative real-time reverse
transcriptase PCR; ELISA, enzyme-linked
immunosorbent assay.
FIG. 7. FACS purification of
transduced BMSCs expres-
sing specific VEGF levels.
Clonal populations of mouse
skeletal myoblasts trans-
duced with the same retrovi-
ral vector expressing rat
VEGF and rat CD8—which
produced specific low,
medium, and high VEGF
levels—were used as refer-
ence populations to FACS-
purify VEGF-producing BMSCs that expressed similar levels of CD8 on the cell surface (A). Quantification of rat VEGF164 by
ELISA (B) shows that FACS sorting was successful in rapidly purifying BMSC populations homogeneously producing the
same VEGF amounts as the corresponding reference populations. *p £ 0.05 and ***p£ 0.001.
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factors despite cell expansion.14 However, current methods
for MSC transduction require that standardized proliferating
cultures are established by replating MSCs at specific den-
sities after the first confluence is reached,31–33 so that until
now a primary genetically modified population could not be
generated before the second passage. In addition, a high
transduction efficiency is desirable, so as to minimize the
need for selection of the expressing cells and for further ex-
pansion to reach the required quantity. Therefore, by rigor-
ously determining the exact time at which freshly isolated
MSCs reach the highest proliferative activity after first plat-
ing, we were able to target retroviral vector transduction at
the most efficient window and achieve a transduction effi-
ciency of up to 95% before first confluence was reached. It
should be noted that initial experiments to determine the
optimal protocol led to efficiencies of only approximately
70% because they were performed with frozen aliquots of
pooled viral vector supernatants in order to ensure stan-
dardized conditions. However, fresh supernatants, which
have higher titers, allowed the routine achievement of > 90%
efficiency with the same protocol.
A crucial aspect of the technique we developed is the
possibility to rapidly and prospectively purify subpopula-
tions of transduced cells expressing specific desired levels of
the transgene. In fact, selection of transduced cells by drug
resistance34 cannot distinguish cells expressing different
transgene levels. On the other hand, although single-cell
cloning can generate populations expressing precisely con-
trolled levels, it is not a clinically applicable approach due to
(1) the excessive degree of in vitro expansion required, which
is incompatible with the maintenance of differentiation po-
tential of human MSCs; and (2) the excessive costs and
complexity associated with generating and screening librar-
ies of clones. Coexpression of a FACS-detectable marker,
for example, green fluorescent protein, without the use of
reference populations also does not allow the predictive
identification of the levels of expression in each cell.35 In fact,
although FACS is intrinsically quantitative, the measured
fluorescence intensity values cannot be directly translated
into absolute amounts of transgene production. Here we
overcame this limitation by taking advantage of a technique
we recently developed to predict the absolute amount of
expression by individual transduced skeletal myoblasts in a
population by FACS, based on the combined use of a syn-
genic nonfunctional cell surface marker (truncated CD8a)
with that of immortal clonal populations as a reference.29 It
can be noted that the CD8 intensity of the high-expressing
purified population shown in Figure 7A corresponded to the
middle peak of the parent unsorted population and, in fact,
the two populations also expressed a similar amount of rat
VEGF (142 and 154 ng/106 cells/day, respectively), con-
firming the predictive validity of the platform.
The possibility to control the expressed dose of a trans-
gene has important therapeutic implications. In fact, in a
heterogeneous population, high levels can be toxic and low
levels inefficient, leading to a waste of therapeutic poten-
tial.10 For example, VEGF overexpression is an attractive
strategy to induce therapeutic angiogenesis in ischemic
conditions,36 as well as to increase and accelerate vasculari-
zation of clinical-size tissue-engineered grafts.37 However,
VEGF can induce either normal and therapeutic angiogene-
sis, or aberrant angioma-like vascular growth depending on
its concentration in the microenvironment around each
producing cell in vivo, and not on its total dose,11,38 as it
remains bound to the extracellular matrix after secretion.
Here we showed that MSC subpopulations homogeneously
producing specific desired VEGF doses can be rapidly and
prospectively purified from the initial transduced population
already at the first passage, with no loss of their proliferation
and differentiation potential, by combining the optimized
transduction protocol and high-throughput FACS-based
purification technology we developed. Furthermore, it
should prove useful also to study the dose-dependent effects
of genes of therapeutic interest on early-passage primary
MSCs. In fact, the results obtained studying heterogeneous
transduced populations usually reflect the effects of the
highest levels of expression, which may obscure those of the
lower and more physiological levels.
Interestingly, in vitro osteogenic differentiation caused an
increased expression of the vector-encoded VEGF in adipose-
derived, but not in bone marrow–derived MSCs, which was
confirmed in three independent donors (Fig. 6C, D). Cell
differentiation involves extensive alterations in gene ex-
pression that depend on chromatin remodeling28 and this
influences the transcriptional activity of the retroviral vectors
integrated in those genomic areas. Therefore, this different
effect on vector activity in ASCs and BMSCs suggests that
osteogenic differentiation of MSCs of different origin might
involve the activation and repression of different genomic
areas. Further transcriptome analyses will be required to
investigate this intriguing possibility.
In conclusion, the platform described here is expected to
increase the feasibility of therapeutic approaches based on
genetically modified MSCs, by ensuring both high efficiency
and minimal in vitro manipulation.
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